Institute of Pharmaceutical Chemistry , Goethe University Frankfurt , Max-von-Laue-Strasse 9 , D-60438 Frankfurt , Germany.
Institute of Pharmaceutical and Medicinal Chemistry , Heinrich Heine University Düsseldorf , Universitaetsstrasse 1 , D-40225 , Duesseldorf , Germany.
J Med Chem. 2019 Jan 24;62(2):420-444. doi: 10.1021/acs.jmedchem.8b00760. Epub 2018 Aug 3.
Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacology holds enormous potential to secure future therapeutic innovation.
包含针对多个生物靶标活性的多靶化合物由于癌症、炎症或代谢综合征等多因素疾病的复杂性而在药物发现中具有重要意义。多药效药物特征可产生相加或协同作用,同时减少副作用,并为阿司匹林等不可或缺药物的高治疗成功率做出重大贡献。虽然它们的鉴定长期以来一直是偶然的结果,但药物化学现在倾向于设计多药效性。现代体外药理学方法和化学探针允许系统地寻找合理的靶标组合,计算技术、晶体学或基于片段的设计方面的最新创新为多靶化合物的开发提供了有价值的工具。在本观点中,我们分析了多配体在药物发现中的相关性以及设计多药效性的多功能工具盒。我们得出的结论是,尽管仍存在一些未解决的特征挑战,但设计的多药效性具有巨大的潜力,可以确保未来的治疗创新。